ArticleJournal of hepatocellular carcinoma2026
Identification of a Prognostic Gene Signature Based on Lenvatinib Resistance in Hepatocellular Carcinoma with Functional Validation of the Key Gene CPB2.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a prevalent and lethal form of liver cancer that necessitates the exploration of innovative strategies due to the limitations of current therapies, including high recurrence rates and drug resistance. Methods: Lenvatinib-resistant Huh7-LR and PLC/PRF/5-LR cell lines were established. RNA sequence analysis was performed to identify differentially expressed genes associated with lenvatinib resistance in HCC tissues. A prognostic model was constructed using Cox regression analysis incorporating eight prognosis-related genes. A nomogram was developed by combining clinical factors and risk scores. Functional validation of the key gene, CPB2, was performed to explore its role in HCC progression and lenvatinib resistance. Results: Lenvatinib-resistant Huh7-LR and PLC/PRF/5-LR cell lines exhibited significant resistance indices of 4.59 and 4.37, respectively. RNA sequence analysis revealed 82 genes associated with lenvatinib resistance that were differentially expressed in HCC tissues. The prognostic model stratified patients into high-risk and low-risk groups with significantly distinct overall survival outcomes (p = 3.057e-05). The nomogram demonstrated high concordance in predicting survival probabilities (AUC = 0.78). CPB2 has emerged as a core gene linked to lenvatinib resistance; low expression of CPB2 in HCC tissues is associated with poor prognosis and promotes HCC progression and lenvatinib resistance via inhibition of the MAPK signaling pathway. Conclusion: These findings underscore the importance of understanding lenvatinib resistance mechanisms, providing a foundation for future therapeutic strategies targeting CPB2, and advancing personalized treatment approaches for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.